BY MARKETWIRE
-
Lundbeck CEO positive about potential for migraine drug in China after strong trial data
Vyepti offered for DKK 774m within the third quarter, in comparison with DKK 444m in Q3 of final 12 months.
-
Jefferies sees no major changes to Lundbeck’s estimates despite upward revision
On Wednesday, Lundbeck raised its full-year steering to 12-14% income progress in native currencies and a 17-20% enhance in adjusted working revenue.
-
Lundbeck’s growth will be determined by Vyepti and Rexulti sales, analysts predict
As in earlier quarters, the massive movers within the third quarter for Lundbeck are anticipated to be the 4 strategic key merchandise.
-
Convatec upgrades guidance
Amongst different issues, the corporate now expects elevated gross sales of seven.5-8% in comparison with the earlier 6-7%.
-
Novo Nordisk put on JPMorgan’s catalyst list ahead of obesity data
JPMorgan’s evaluation predicts that cagrisema can obtain a median weight lack of 25.1%.
-
Jefferies: Allergic shock spray license is attractive with clear synergies for ALK
The nasal spray can also be thought-about to have extra advantages than different obtainable therapies available on the market which are administered through injection.
-
GN’s earnings outperform prognosis despite revenue pressured by negative organic growth
The business downgrades full-year development assumptions.
-
Coloplast CEO gets pay cut after smaller bonus
The remuneration bundle consists of a base wage of DKK 12.3 million, however on the similar time the money bonus has been halved.
-
Genmab to release 20 abstracts at hematology conference
(*) New scientific outcomes for the therapy of non-hodgkin’s lymphoma will certainly exist at the American Culture of Hematology (ASH) seminar in December.( *).
-
Catalent surprises with loss – predicts transaction towards year-end
Both the leading and profits let down contrasted to market assumptions.
